Astrea Bioseparations joins Biotage, enabling ground breaking chromatography solutions

Astrea Bioseparations now part of Biotage

Biotage has completed the acquisition of Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences, a life sciences tools platform created by KKR.

Astrea’s over 150 employees worldwide will join Biotage, and the company’s production sites in Cambridge, UK, Isle of Man, Boston, USA, and Joliette, Canada become an important part of Biotage’s global presence.

Biotage’s expanded portfolio will now include chromatography resins, absorbents, and columns as well as nanofiber-based purification technologies, serving biologics and advanced therapeutic customers. This complements the company’s existing purification solutions predominantly targeting small molecules and synthetic therapeutics.

Tomas Blomquist, CEO and President at Biotage, said: “The acquisition of Astrea Bioseparations allows us to build a transformative platform company within chromatography targeting both small and large molecules. With Astrea’s expert team and broad product portfolio with a near-term pipeline of product launches we are now well-equipped to target biologics and the new modalities emerging in the biopharma industry.”

Terry Pizzie, CEO, Astrea Bioseparations, said: "Joining forces with Biotage marks an exciting chapter for Astrea Bioseparations. By combining the expertise of our teams alongside our innovative product offerings, we are well-positioned to drive novel breakthroughs in the chromatography sector. Together, we can provide comprehensive solutions to meet the evolving needs of the biopharma industry, particularly in the realm of biologics and advanced therapeutics. This collaboration opens up new avenues for growth and underscores our commitment to delivering exceptional chromatography solutions."

Kieran Murphy and Kugan Sathiyanandarajah become new members of the Biotage board of directors. The appointments were approved at the Biotage annual general meeting held on 27 April 2023 and they were conditional upon the completion of the Astrea Bioseparations transaction.
About Biotage

Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing, and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener, and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.Website: www.biotage.com

Contacts: Tomas Blomquist, President and CEO
[email protected]